

The following Claims will be amended to recite:

- Claim 1: A purified cyclic peptide that selectively binds to colon cancer cells wherein said peptide has the formula A-X1-X2-X3-X4-X5-X6-X7-X8-X9-B, wherein the sequence X6-X7-X8 is arg-pro-met.
- Claim 3: The peptide according to Claim 1 wherein said peptide....residues.
- Claim 4: The peptide according to claim 1, wherein X1-X9 each are an amino acid, wherein A and B are absent or peptides containing up to 6 amino acids, and wherein amino acids X2, X3, X4, and X5 may be the same or different and each optionally may be absent.
- Claim 8: The peptide according to claim 6 wherein X2 is pro, X3 is selected from the group consisting of ile and leu; X4 is selected from the group consisting of glu, asp, and arg; and X5 is selected from the group consisting of asp and glu.
- Claim 10: A composition comprising at least two peptides according to any one of claims 1-6 and 8.
- Claim 25: A purified cyclic polypeptide represented by the formula A-cys-X1-X2-X3-X4-arg-pro-met-cys-B (SEQ ID NO: 139), wherein X1-X4 each are an amino acid, and wherein A and B are absent or peptides containing up to 6 amino acids.
- Cancel Claim 2 in view of amendment to Claim 1
- Cancel Withdrawn Claims 15-18 and 21-24 as being drawn to non-elected inventions.